Publications Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease Citation Lefevre PLC, Vande Casteele N. Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease. J Crohns Colitis. 2020 Aug 1;14(Supplement_2):S725-S736. doi: 10.1093/ecco-jcc/jjaa014. PMID: 32160283; PMCID: PMC7395308. Abstract Inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, are chronic inflammatory disorders of the gastrointestinal tract which are characterised, in part, by an imbalance in the production of several pro- and anti-inflammatory cytokines. Tags Adverse Effects, Drug Therapy, Heterocyclic Compounds 3-Ring, IBD, Inflammatory Bowel Disease, Janus kinase inhibitors, Janus kinases, Pharmacology, Piperidines, Pyrazoles, Pyrimidines, Pyrroles, therapeutic use, Triazoles Read More
